本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600569 证券简称：安阳钢铁 编号：2025—084 安阳钢铁股份有限公司 2025 年上半年主要经营数据公告 本公告经营数据未经审计，请投资者注意投资风险并审慎使用。 特此公告。 安阳钢铁股份有限公司董事会 2025 年 8 月 28 日 主要产品 产量（万吨） 销量（万吨） 销售价格 （元/吨） 板带材 371.94 368.50 3,210.33 其他 61.50 61.31 2,961.98 二、公司 2025 年 1-6 月主要品种产量、销量、销售价格情况 根据上海证券交易所《上海证券交易所上市公司自律监管指引 第 3 号—行业信息披露》要求，公司将 2025 年上半年主要经营数据 公告如下： 一、公司主要财务数据 单位：元 币种：人民币 | 主要会计数据 | 本报告期 | 上年同期 | 本报告期比上年 同期增减(%) | | --- | --- | --- | --- | | | 2025 年 1-6 月 | 2024 年 1-6 月 | | | ...

| 证券代码：605337 | 证券简称：李子园 | 公告编号：2025-062 | | --- | --- | --- | | 转债代码：111014 | 转债简称：李子转债 | | 浙江李子园食品股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江李子园食品股份有限公司(以下简称"公司") 根据上海证券交易所《上海 证券交易所上市公司自律监管指引第 3 号——行业信息披露》的有关规定，现将公 司 2025 年半年度的主要经营数据（未经审计）公告如下： 一、主要业务经营情况 (一)主营业务按产品类别分类情况 单位：元 币种：人民币 (三)主营业务按地区分布分类情况 单位：元 币种：人民币 销售模式 2025 年半年度营业收入 2024 年半年度营业收入 同比增长幅度 经销 585,047,720.29 645,252,695.67 -9.33% 直销 33,412,905.04 30,970,662.58 7.89% 合计 618,460,625.33 676,223 ...

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025 compared to the same period in 2024, indicating challenges in its financial performance [1] Group 1: Financial Performance - The company's revenue decreased by 4.84% to 6.95 billion yuan in the first half of 2025, while net profit fell by 9.46% to 2.229 billion yuan [1] - In Q2 2025, the company's revenue was 1.852 billion yuan, representing a year-on-year decline of 29.69%, and net profit was 0.585 billion yuan, down 37.06% year-on-year [1] Group 2: Revenue by Product - Revenue from Special A+ products in the first half of 2025 was 4.311 billion yuan, a decrease of 7.3% compared to 4.654 billion yuan in the same period of 2024 [2] - Revenue from Special A products increased slightly by 0.74% to 2.232 billion yuan, while A class products saw a decline of 10% to 0.232 billion yuan [2] - B class products revenue decreased by 6.3% to 0.077 billion yuan, and revenue from C and D class products dropped significantly by 39.3% to 0.026 billion yuan [2] - Other products experienced a revenue decline of 9.8% to 0.028 billion yuan [2] Group 3: Revenue by Region - Revenue from domestic sales was 6.254 billion yuan, down 6% from 6.658 billion yuan in the previous year [2] - The Huai'an region generated 1.226 billion yuan, a decrease of 4.3%, while the Nanjing region saw a decline of 7.9% to 1.753 billion yuan [2] - The Chinan region's revenue fell by 11% to 0.728 billion yuan, while the Chizhong region remained relatively stable with a slight decrease of 0.2% to 1.116 billion yuan [2] - The Yancheng region's revenue decreased by 6.31% to 0.753 billion yuan, and the Huaihai region's revenue dropped by 7.3% to 0.677 billion yuan [2] - Conversely, revenue from outside the province increased by 4.78% to 0.628 billion yuan [2]

股票代码：600399 股票简称：抚顺特钢 编号：临 2025-037 抚顺特殊钢股份有限公司 2025 年半年度经营数据公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 | 产品名称 | 经营指标 | 2025 年 1-6 | 月 | 2024 年 1-6 月 | 增减情况（%） | | --- | --- | --- | --- | --- | --- | | 合金结构 | 产量（万吨） | 9.67 | | 10.89 | -11.22 | | 钢 | 销量（万吨） | 9.57 | | 11.29 | -15.26 | | | 平均售价（元/吨，不含税） | 10,863.72 | | 13,287.79 | -18.24 | | 工具钢 | 产量（万吨） | 4.54 | | 3.93 | 15.46 | | | 销量（万吨） | 4.58 | | 4.20 | 9.08 | | | 平均售价（元/吨，不含税） | 16,847.88 | | 16,856.84 | -0.05 | | 不锈钢 ...

Company Overview - Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, development, production, and sales of disposable medical consumables [1] - The main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - For Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - The net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The gross profit margin stood at 32.40% [1] Market Position - As of August 22, the company's stock closed at 20.45 yuan, down 1.06%, with a rolling PE ratio of 29.29 times [1] - The total market capitalization is 4.509 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing Gongdong Medical at the 58th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 8,909, up by 735 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Core Viewpoint - The financial report of Hunan Wuxin Tunnel Intelligent Equipment Co., Ltd. indicates a decline in revenue and net profit for the first quarter of 2025 compared to the same period in 2024, alongside an increase in net assets and significant changes in cash flow and asset management [1][2][3]. Financial Data Summary - Total assets as of March 31, 2025, amounted to CNY 1,084.53 million, a decrease of 2.01% from the end of 2024 [1]. - Net assets attributable to shareholders increased by 4.36% to CNY 797.51 million compared to the previous year [1]. - The company's debt-to-asset ratio decreased from 31.85% to 27.36% for the parent company and from 30.96% to 26.46% for the consolidated entity [1]. - Revenue for the first quarter of 2025 was CNY 172.57 million, down 10.77% year-on-year, while net profit attributable to shareholders decreased by 11.04% to CNY 32.20 million [1][2]. - The basic earnings per share fell by 12.20% to CNY 0.36 [1]. Revenue Composition - Revenue from the main product category was CNY 155.94 million, with a gross margin of 31.58%, reflecting a decrease of 12.63% in revenue and a decline of 9.35% in cost compared to the previous year [2]. - The company reported a significant increase in cash flow from operating activities, which rose by 1,739.57% to CNY 30.74 million [1][3]. Significant Changes in Assets and Liabilities - The company increased its trading financial assets by 85.87% to CNY 130.18 million, indicating a strategic shift in asset management [2]. - Prepayments to suppliers increased by 42.07%, while other current assets decreased by 52.60% [2]. - The company reported a substantial increase in advance payments received from customers, which rose by 428.31% [3]. Major Events and Corporate Actions - The company established a wholly-owned subsidiary in Hangzhou, Zhejiang Province, as approved in the first temporary shareholders' meeting of 2025 [12]. - The company is in the process of acquiring 100% equity of Hunan Zhongtie Wuxin Heavy Industry Co., Ltd. and Huaihua Xingsheng Technology Co., Ltd. through a combination of share issuance and cash payment [14].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Gongdong Medical, which closed at 20.96 yuan, up 3.76%, with a rolling PE ratio of 30.02, marking a new low in 33 days, and a total market capitalization of 4.622 billion yuan [1][2] - Gongdong Medical's PE ratio is significantly lower than the industry average of 55.70 and the industry median of 39.08, ranking 58th in the medical device sector [1][2] - As of March 31, 2025, Gongdong Medical had 8,909 shareholders, an increase of 735 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Gongdong Medical specializes in the research, production, and sales of disposable medical consumables, with key products including medical testing, blood collection, collection, medical care, and drug packaging [1] - The latest quarterly report for Q1 2025 shows Gongdong Medical achieved revenue of 264 million yuan, a year-on-year decrease of 2.74%, and a net profit of 27.41 million yuan, down 39.23%, with a gross profit margin of 32.40% [1]

Company Overview - Company name: Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - Main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - As of Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - Net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The sales gross margin stood at 32.40% [1] Market Position - The company's current stock price is 19.83 yuan, with a PE ratio of 28.40 times [1] - Total market capitalization is 4.372 billion yuan [1] - Compared to the industry average PE of 54.56 times and median PE of 37.54 times, the company ranks 56th in the medical device sector [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 8,909, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Company Overview - Company name: Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - Main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - As of Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - Net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The sales gross margin stood at 32.40% [1] Market Position - The company's closing stock price on July 4 was 20.72 yuan, with a PE ratio of 29.68 times [1] - The total market capitalization is 4.569 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 51.05 times, with a median of 36.62 times, placing Gongdong Medical at the 66th position in the industry [1][2] Institutional Holdings - As of Q1 2025, four institutions hold shares in Gongdong Medical, including two funds, with a total holding of 14.5259 million shares valued at 402 million yuan [1]

证券代码：600569 证券简称：安阳钢铁 编号：2025-037 安阳钢铁股份有限公司 2025 年第一季度主要经营数据公告 安阳钢铁股份有限公司董事会 2025 年 4 月 28 日 主要 产品 产量（万吨） 销量（万吨） 销售价格 （元/吨） 板带材 177.87 170.98 3,265.14 其他 27.90 28.22 3,006.81 二、公司 2025 年 1-3 月主要品种产量、销量、销售价格情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号—行业信息披 露》要求，公司将 2025 年第一季度主要经营数据公告如下： 一、公司主要财务数据 主要会计数据 2025 年 1-3 月 2024 年 1-3 月 本报告期比上年 同期增减(%) 营业收入 7,443,574,570.49 8,507,632,906.16 -12.51 归属于上市公司股东的净利润 18,291,831.47 -483,950,766.71 不适用 归属于上市公司股东的扣除非 经常 ...